Cancer Research Cancer Epigenetics  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 43, 541-545, February 1, 1983]
© 1983 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berdel, W. E.
Right arrow Articles by Snyder, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berdel, W. E.
Right arrow Articles by Snyder, F.

Cytotoxicity of Alkyl-lysophospholipid Derivatives and Low-Alkyl-Cleavage Enzyme Activities in Rat Brain Tumor Cells

Wolfgang E. Berdel1, Eva Greiner2, Ulrich Fink, Dimitrios Stavrou, Anneliese Reichert, Johann Rastetter, Dennis R. Hoffman and Fred Snyder4

Division of Hematology and Oncology, Department of Medicine I, Technical University [W. E. B., E. G., U. F., A. R., J. R.], and Department of Functional Pathology, Ludwig-Maximilians-University [D. S.], 8000 Munich, Federal Republic of Germany, and the Medical and Health Sciences Division, Oak Ridge Associated Universities, Oak Ridge, Tennessee 37830 [D. R. H., F. S.]

Alkyl-lysophospholipids (ALP) and related derivatives inhibited the in vitro incorporation of [3H]thymidine into seven different permanent cell lines derived from rat brain tumors. The cytostatic effect of ALP was dependent on dosage and incubation time. Naturally occurring 2-lysophosphatidylcholine did not exhibit cytostatic effects; under these conditions, the incorporation rates of [3H]thymidine were generally more than 100% of the controls. The trypan blue dye exclusion test, which was used to assess severe cell damage, correlated with the extent that [3H]thymidine incorporation was inhibited by ALP.

Preincubation of ALP (rac-1-octadecyl-lyso-glycero-3-phosphocholine) for more than 8 min with a tetrahydropteridine-dependent O-alkyl cleavage enzyme preparation from rat liver microsomes destroyed almost all of the cytotoxic properties of ALP when tested at a concentration that previously inhibited tumor growth by more than 50%. [3H]Thymidine incorporation rates were greater than 100% for astrocytoma cells incubated with ALP after exposure to the alkyl cleavage enzyme.

Comparison of the microsomal activities of the tetrahydropteridine-dependent alkyl-cleavage enzyme present in astrocytoma 78-FR-G-299 cells and the pleomorphic glioma 78-FR-G-219/S4 cells to that found in normal skin fibroblasts and rat livers revealed a markedly reduced activity in the neoplastic cell lines. Moreover, those tumor cells that were more resistant to ALP cytotoxicity (pleomorphic glioma, 78-FR-G-219/S4) had a 3-fold higher tetrahydropteridine-dependent cleavage activity than a more cytotoxic sensitive line (astrocytoma cells, 78-FR-G-299). Our results indicate that the low-alkyl-cleavage enzyme activities in these neoplastic cells in comparison to normal cells might be a factor in explaining the relatively high cytotoxicity of ALP in tumor cells.

1 Supported by Deutsche Forschungsgemeinschaft Grants Be 822/2-2 and Sta 134/2. To whom requests for reprints should be addressed: Division of Hematology and Oncology, Department of Medicine I, Technical University, Ismaninger Str. 22, 8000 Munich 80, Federal Republic of Germany.

2 In partial fulfillment of the M.D. degree of the Technical University of Munich.

3 Fellowship supported by Grant CA 09336 awarded by the National Cancer Institute to the University of Tennessee and the Oak Ridge National Laboratory.

4 Supported by the Office of Energy Research, United States Department of Energy (Contract DE-AC05-760R00033), and the American Cancer Society (Grant BC-70M).

Received 11/19/81. Accepted 11/ 4/82.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1983 by the American Association for Cancer Research.